Kaneka (4118) Q2 2027 earnings summary

Executive summary

• H1 FY2027 net sales rose 12.5% YoY to ¥446,972 million and operating income rose 91.7% to ¥28,678 million; both were first-half records, with growth across all business units.

• Net income attributable to owners increased 32.5% YoY to ¥14,645 million; expanding Health Care and Supplemental Nutrition priorities supported growth.

Financial highlights

• Ordinary income rose 106.8% YoY to ¥24,323 million; operating margin expanded to 6.4% from 3.8%.

• Gross profit was ¥131,312 million, versus ¥108,525 million a year earlier; basic EPS was ¥243.48.

• Comprehensive income was ¥15,954 million, versus ¥14,540 million; net income was ¥15,790 million, versus ¥11,808 million.

Outlook and guidance

• FY2027 forecast revised to net sales ¥890,000 million, operating income ¥48,000 million, ordinary income ¥41,500 million and net income attributable to owners ¥32,000 million; forecast EPS is ¥536.33.

• Versus the prior forecast, sales increased ¥70,000 million, operating income ¥12,000 million, ordinary income ¥9,500 million and net income ¥500 million.

• FY2027 annual dividend forecast rose to ¥215/share, including ¥105/share paid at the interim date; year-end forecast is ¥110/share.

• Growth priorities include Health Care, high-value-added Quality of Life products, Supplemental Nutrition and premium Foods & Agris products.